Literature DB >> 19554431

Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design.

Hanna E Silber1, Joakim Nyberg, Andrew C Hooker, Mats O Karlsson.   

Abstract

Intravenous glucose tolerance test (IVGTT) provocations are informative, but complex and laborious, for studying the glucose-insulin system. The objective of this study was to evaluate, through optimal design methodology, the possibilities of more informative and/or less laborious study design of the insulin modified IVGTT in type 2 diabetic patients. A previously developed model for glucose and insulin regulation was implemented in the optimal design software PopED 2.0. The following aspects of the study design of the insulin modified IVGTT were evaluated; (1) glucose dose, (2) insulin infusion, (3) combination of (1) and (2), (4) sampling times, (5) exclusion of labeled glucose. Constraints were incorporated to avoid prolonged hyper- and/or hypoglycemia and a reduced design was used to decrease run times. Design efficiency was calculated as a measure of the improvement with an optimal design compared to the basic design. The results showed that the design of the insulin modified IVGTT could be substantially improved by the use of an optimized design compared to the standard design and that it was possible to use a reduced number of samples. Optimization of sample times gave the largest improvement followed by insulin dose. The results further showed that it was possible to reduce the total sample time with only a minor loss in efficiency. Simulations confirmed the predictions from PopED. The predicted uncertainty of parameter estimates (CV) was low in all tested cases, despite the reduction in the number of samples/subject. The best design had a predicted average CV of parameter estimates of 19.5%. We conclude that improvement can be made to the design of the insulin modified IVGTT and that the most important design factor was the placement of sample times followed by the use of an optimal insulin dose. This paper illustrates how complex provocation experiments can be improved by sequential modeling and optimal design.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19554431     DOI: 10.1007/s10928-009-9123-y

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  18 in total

1.  The iterative two-stage population approach to IVGTT minimal modeling: improved precision with reduced sampling. Intravenous glucose tolerance test.

Authors:  P Vicini; C Cobelli
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-01       Impact factor: 4.310

2.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.

Authors:  S Retout; S Duffull; F Mentré
Journal:  Comput Methods Programs Biomed       Date:  2001-05       Impact factor: 5.428

3.  Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics.

Authors:  Sylvie Retout; France Mentré
Journal:  J Biopharm Stat       Date:  2003-05       Impact factor: 1.051

4.  POPED, a software for optimal experiment design in population kinetics.

Authors:  Marco Foracchia; Andrew Hooker; Paolo Vicini; Alfredo Ruggeri
Journal:  Comput Methods Programs Biomed       Date:  2004-04       Impact factor: 5.428

5.  Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.

Authors:  Henrik Agersø; Paolo Vicini
Journal:  Eur J Pharm Sci       Date:  2003-06       Impact factor: 4.384

6.  Intravenous glucose tolerance as a tool in definition and diagnosis of diabetes mellitus.

Authors:  K LUNDBAEK
Journal:  Br Med J       Date:  1962-06-02

7.  Approaches to handling pharmacodynamic baseline responses.

Authors:  Chantaratsamon Dansirikul; Hanna E Silber; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-04-30       Impact factor: 2.745

Review 8.  Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Authors:  Cornelia B Landersdorfer; William J Jusko
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

9.  A reduced sampling schedule for estimating the parameters of the glucose minimal model from a labeled IVGTT.

Authors:  C Cobelli; A Ruggeri
Journal:  IEEE Trans Biomed Eng       Date:  1991-10       Impact factor: 4.538

10.  The insulin sensitivity index in nondiabetic man. Correlation between clamp-derived and IVGTT-derived values.

Authors:  J C Beard; R N Bergman; W K Ward; D Porte
Journal:  Diabetes       Date:  1986-03       Impact factor: 9.461

View more
  5 in total

1.  D optimal designs for three Poisson dose-response models.

Authors:  Alan Maloney; Ulrika S H Simonsson; Marloes Schaddelee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-19       Impact factor: 2.745

2.  Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.

Authors:  Vidya Perera; Robert R Bies; Gary Mo; Michael J Dolton; Vaughan J Carr; Andrew J McLachlan; Richard O Day; Thomas M Polasek; Alan Forrest
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

3.  Reduced and optimized trial designs for drugs described by a target mediated drug disposition model.

Authors:  A Brekkan; S Jönsson; M O Karlsson; A C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-06-08       Impact factor: 2.745

4.  Model-Based Interspecies Scaling of Glucose Homeostasis.

Authors:  Oskar Alskär; Mats O Karlsson; Maria C Kjellsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-09-28

Review 5.  Development of early diagnosis of Parkinson's disease: Illusion or reality?

Authors:  Michael Ugrumov
Journal:  CNS Neurosci Ther       Date:  2020-06-29       Impact factor: 7.035

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.